The clinical aspects of effectiveness of incretin therapy (WNT-pathogenic path and polymorphism of gene TCF7L2)

Abstract


The article considers genetic susceptibility to development of diabetes mellitus type II, its micro-vascular complications and intensity of response under application of incretin therapy depending on carriage of polymorphism of gene TCF7L2 involved into WNT-path and incretin axis.

Full Text

Restricted Access

About the authors

A. S Ametov

The Russian medical academy of post-graduate education of Minzdrav of Russia

123995, Moscow, Russia

Lyudmila L. Kamynina

The Russian medical academy of post-graduate education of Minzdrav of Russia

Email: petrology@yandex.ru
123995, Moscow, Russia
MD, PhD

Z. G Akhmedova

The A. Aliev Azerbaijan state institute of post-graduate training of physicians

370012, Baku, Republic of Azerbaydzhan

References

  1. Tuomi T., Santoro N., Caprio S., Cai M., Weng J., Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014; 383(9922): 1084-94.
  2. Kato N. Insights into the genetic basis of type 2 diabetes. J. Diabetes Investig. 2013; 4(3): 233-44.
  3. Chiang Y.T., Ip W., Jin T. The role of the Wnt signaling pathway in incretin hormone production and function. Front. Physiol. 2012; 3: 273.
  4. Ip W., Shao W., Chiang Y.T., Jin T. The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis. Am. J. Physiol. Endocrinol. Metab. 2012; 303(9): E1166-76.
  5. Xiong X., Shao W., Jin T. New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin. Islets. 2012; 4(6): 359-65.
  6. Nobrega M.A. TCF7L2 and glucose metabolism: time to look beyond the pancreas. Diabetes. 2013; 62(3): 706-8.
  7. Howard E.W., Been L.F., Lerner M., Brackett D., Lightfoot S., Bullen E.C. et al. Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2. BMC Genet. 2013; 14: 28.
  8. Shu L., Matveyenko A.V., Kerr-Conte J., Cho J.H., McIntosh C.H., Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum. Mol. Genet. 2009; 18(13): 2388-99.
  9. Zampetti S., Spoletini M., Petrone A., Capizzi M., Arpi M.L., Tiberti C. et al. Association of TCF7L2 gene variants with low GAD autoantibody titre in LADA subjects (NIRAD Study 5). Diabet Med. 2010; 27(6): 701-4.
  10. Peng S., Zhu Y., Lü B., Xu F., Li X., Lai M. TCF7L2 gene polymorphisms and type 2 diabetes risk: a comprehensive and updated metaanalysis involving 121174 subjects. Mutagenesis. 2013; 28(1): 25-37.
  11. Никитин А.Г., Потапов В.А., Бровкин А.Н., Лаврикова Е.Ю., Ходырев Д.С., Шамхалова М.Ш. и др. Ассоциация полиморфных маркеров гена TCF7L2 с сахарным диабетом типа 2. Клиническая практика. 2014; 14: 4-11.
  12. Franceschini N., Shara N.M., Wang H., Voruganti V.S., Laston S., Haack K. et al. The association of genetic variants of type 2 diabetes with kidney function. Kidney Int. 2012; 82(2): 220-5.
  13. Buraczynska M., Zukowski P., Ksiazek P., Kuczmaszewska A., Janicka J., Zaluska W. Transcription factor 7-like 2 (TCF7L2) gene polymorphism and clinical phenotype in end-stage renal disease patients. Mol. Biol. Rep. 2014; 41(6): 4063-8.
  14. Железнякова А.В., Лебедева Н.О., Викулова О.К., Носиков В.В., Шамхалова М.Ш., Шестакова М.В. Риск развития хронической болезни почек у больных сахарным диабетом 2 типа детерминирован полиморфизмом генов NOS3, APOB, KCNJ11, TCF7L2. Сахарный диабет. 2014; 3: 23-30.
  15. Zimdahl H., Ittrich C., Graefe-Mody U., Boehm B.O., Mark M., Woerle H.J. et al. Infl uence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia. 2014; 57(9): 1869-75.
  16. Mattei J., Qi Q., Hu F.B., Sacks F.M., Qi L. TCF7L2 genetic variants modulate the effect of dietary fat intake on changes in body composition during a weight-loss intervention. Am. J. Clin. Nutr. 2012; 96(5): 1129-36.
  17. Villareal D.T., Robertson H., Bell G.I., Patterson B.W., Tran H., Wice B. et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes. 2010; 59(2): 479-85.

Statistics

Views

Abstract - 32

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies